Patents by Inventor Kristen Pierce
Kristen Pierce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230052212Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.Type: ApplicationFiled: August 8, 2022Publication date: February 16, 2023Inventors: Kristen PIERCE, Janine POWERS, Servando PALENCIA, Robert SIKORSKI, Majid GHODDUSI, Kartik KRISHNAN
-
Patent number: 11447553Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.Type: GrantFiled: November 22, 2016Date of Patent: September 20, 2022Inventors: Kristen Pierce, Janine Powers, Servando Palencia, Robert Sikorski, Majid Ghoddusi, Kartik Krishnan
-
Publication number: 20220168416Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.Type: ApplicationFiled: December 17, 2021Publication date: June 2, 2022Applicant: Five Prime Therapeutics, Inc.Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
-
Patent number: 11235059Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.Type: GrantFiled: November 6, 2018Date of Patent: February 1, 2022Assignee: Five Prime Therapeutics, Inc.Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
-
Publication number: 20210340214Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1) to a subject in need thereof, for example, a cancer patient.Type: ApplicationFiled: August 28, 2019Publication date: November 4, 2021Inventors: Sandeep P. INAMDAR, Kristen PIERCE, Hong XIANG, Susannah D. BARBEE
-
Publication number: 20190175730Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.Type: ApplicationFiled: November 6, 2018Publication date: June 13, 2019Applicant: Five Prime Therapeutics, Inc.Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
-
Patent number: 10172937Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.Type: GrantFiled: May 27, 2016Date of Patent: January 8, 2019Assignee: Five Prime Therapeutics, Inc.Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
-
Publication number: 20170145103Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides. This application also provides methods of predicting response to treatment of cancer, such as bladder or gastric cancer, with FGFR2 inhibitors by determining FGFR2 overexpression and/or gene amplification in tumor cells of cancer subjects before treatment with FGFR2 inhibitors either alone or in combination with immune stimulating agents.Type: ApplicationFiled: November 22, 2016Publication date: May 25, 2017Applicant: Five Prime Therapeutics, Inc.Inventors: Kristen Pierce, Janine Powers, Servando Palencia, Robert Sikorski, Majid Ghoddusi, Kartik Krishnan
-
Publication number: 20170145102Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.Type: ApplicationFiled: November 22, 2016Publication date: May 25, 2017Applicant: Five Prime Therapeutics, Inc.Inventors: Kristen Pierce, Janine Powers, Servando Palencia, Robert Sikorski, Majid Ghoddusi, Kartik Krishnan
-
Publication number: 20160339100Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.Type: ApplicationFiled: May 27, 2016Publication date: November 24, 2016Applicant: Five Prime Therapeutics, Inc.Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
-
Publication number: 20150050273Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.Type: ApplicationFiled: July 31, 2014Publication date: February 19, 2015Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
-
Publication number: 20100183620Abstract: The invention encompasses methods and compositions for increasing or decreasing collagen 1A1 expression and/or ?-smooth muscle actin expression in lung fibroblasts using SERPINE2 and antagonists of SERPINE2. The invention also encompasses methods and compositions for increasing or decreasing the formation of myofibroblasts. The invention further provides methods and compositions for treatment of lung diseases, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.Type: ApplicationFiled: November 25, 2009Publication date: July 22, 2010Inventors: KAUMUDI BHAWE, Elizabeth Bosch, Kathleen Boyle, Arthur Brace, Anuk Das, Francis Farrell, Pitchumani Sivakumar, Jeffrey Finer, Kristen Pierce, Kathleen M. Sullivan, Brian Wong
-
Publication number: 20080254033Abstract: The present invention provides LRP4, LRP8 and LRP2 (megalin) polypeptides; polynucleotides encoding such; modulators of LRP4, LRP8 and LRP2 activity; and pharmaceutical compositions for the treatment of diseases. Compositions of the invention contain a pharmaceutically acceptable carrier or excipient and at least one modulator that is capable of binding to or interfering with the activity of LRP4, LRP8, LRP2 and active fragments thereof. The invention provides modulators, such as antibodies, RNAi molecules, anti-sense molecules and ribozymes. Additionally, the invention includes methods for the treatment of diseases, such as proliferative diseases and degenerative diseases, and methods of administration of the compositions of the invention.Type: ApplicationFiled: January 21, 2005Publication date: October 16, 2008Inventors: Kristen Pierce, Amy L.Tsui Collins, Hongbing Zhang, Lewis Thomas Williams, Pierre Alvaro Beaurang
-
Publication number: 20080112937Abstract: Aspects of the present invention relate to compositions and methods of reprogramming a somatic cell to give rise to an autologous embryonic stem cell. These methods involve providing a somatic cell of a donor subject, introducing the somatic cell into an embryo of a recipient subject to produce a chimeric embryo, allowing the chimeric embryo to develop further wherein the somatic cell will reprogram, and then selecting an autologous embryonic stem cell that has developed from the somatic cell. The methods and composition of producing pluripotent embryonic stem cells from a donor's own somatic cells invite the possibility of a number of therapeutic applications, including organ transplant and treatment of autoimmune diseases, cancer, and degenerative disorders such as diabetes, Alzheimer's, and Parkinson's.Type: ApplicationFiled: July 19, 2005Publication date: May 15, 2008Inventors: Lewis T Williams, Hongbing Zhang, Srinivas Kothakota, Kristen Pierce, Pierre Alvaro Beaurang, Keting Chu
-
Publication number: 20080014594Abstract: Modulators of phosphatidic acid phosphatase type 2C and other polypeptides, highly expressed in cancers as compared to normal tissues, are provided for treatment of proliferative disorders such as cancer. A method is provided for detecting polypeptides that are overexpressed in cancer, whereby antibodies or binding proteins that specifically recognize these molecules are contacted with a patient's bodily fluid. The method provides an early diagnosis of cancer, and can detect recurrence and metastasis following an initial diagnosis. The invention further provides methods of treating cancer with therapeutic agents directed toward these protein and peptide biomarkers.Type: ApplicationFiled: January 30, 2004Publication date: January 17, 2008Inventors: Kevin Hestir, Ernestine Lee, Keting Chu, Yan Wang, Kristen Pierce, Amy L. Tsui Collins, Lewis Thomas Williams
-
Publication number: 20070248605Abstract: A composition is provided that contains a polypeptide and a modulator or a cell comprising the polypeptide and a modulator, where the modulator specifically interferes with the activity of the polypeptide, and the polypeptide is either FGFR3 or FGFR4, inclusive of all polymorphic forms and variants thereof. The modulator can be an antibody or active fragments thereof, a small molecule drug, an RNAi molecule, an antisense molecule or a ribozyme. A method of treatment of tumors in a subject is also provided where an antagonist of FGFR3 or FGFR4 is administered to the subject.Type: ApplicationFiled: December 17, 2004Publication date: October 25, 2007Applicant: Five Prime Therapetutics, Inc.Inventors: Kevin Hestir, Kristen Pierce, Lewis Williams, Lorianne Masuoka, Justin Wong, Keting Chu